ACLX
Arcellx, Inc.
NASDAQ · Healthcare · Biotechnology · US
$115.07
+0.02%Latest reported
- Last report date
- Nov 5, 2025
- EPS actual
- -$0.99
- EPS estimate
- -$0.96
- Revenue actual
- $4.9M
- Revenue estimate
- $12.6M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -16.8%
- Revenue beats (12Q)
- 3
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Nov 5, 2025 | -$0.96 | -$0.99 | Miss -3.13% | $4.9M |
| Aug 7, 2025 | -$1.03 | -$0.94 | Beat 8.74% | $7.6M |
| May 8, 2025 | -$0.84 | -$1.13 | Miss -34.52% | $8.1M |
| Feb 27, 2025 | -$0.63 | -$0.87 | Miss -38.10% | $15.3M |
| Nov 7, 2024 | -$0.54 | -$0.48 | Beat 11.11% | $26.0M |
| Aug 8, 2024 | -$0.54 | -$0.51 | Beat 5.56% | $27.4M |
| May 9, 2024 | -$0.51 | -$0.14 | Beat 72.55% | $39.3M |
| Feb 28, 2024 | -$0.61 | $0.42 | Beat 168.85% | $63.1M |
| Aug 14, 2023 | -$0.68 | -$0.50 | Beat 26.47% | $14.3M |
| Nov 14, 2022 | -$0.93 | -$0.68 | Beat 26.88% | — |
| Aug 15, 2022 | -$1.20 | -$0.88 | Beat 26.67% | — |
| May 12, 2022 | -$0.95 | -$1.56 | Miss -64.21% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of May 7, 2026